Single-use Bioprocessing Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 1.36 Billion |
| Market Size (2029) | USD 2.9 Billion |
| CAGR (2024 - 2029) | 16.26 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Single-use Bioprocessing Market Analysis
The Single-use Bioprocessing Market size is estimated at USD 1.36 billion in 2024, and is expected to reach USD 2.9 billion by 2029, at a CAGR of 16.26% during the forecast period (2024-2029).
Factors such as faster implementation of single-use bioprocessers and lower risk of product cross-contamination, increasing demand for biopharmaceuticals, lower costs, and lesser environmental impact of single-use bioprocessing technologies are expected to boost market growth.
The demand for biopharmaceuticals is increasing due to the high population suffering from chronic diseases. This raises the need for effective drugs and products for their treatment. For instance, according to the data updated by the Spanish Network of Cancer Registries (REDECAN) in January 2023, about 279,260 new cases of cancer were diagnosed in Spain at the end of 2023, out of which 42,721 were colorectal cancer, 31,282 were lung cancer, and 21,694 were urinary bladder cancer. Thus, with the growing burden of cancer among the population, the demand for novel drugs and therapies is expected to increase, which, in turn, is anticipated to boost demand for single-use technologies and related products for drug development, thereby propelling market growth.
Additionally, the increasing adoption of single-use technologies and products across biopharmaceutical companies to reduce the risk of cross-contamination is further expected to fuel market growth over the forecast period. For instance, in April 2023, Cytiva, an American-based company, launched X-platform bioreactors to streamline the single-use upstream bioprocessing operations. The newly launched bioreactors boost process efficiency via production capability, ergonomic improvements, and streamlined supply chain operations. This rapid implementation allows manufacturers to respond swiftly to changing market demands and production schedules, which is expected to increase operational efficiency and upsurge the growth of the single-use bioprocessing market over the forecast period.
Furthermore, the advantages offered by single-use systems propel their adoption across the biopharmaceutical industry, boosting market growth. For instance, according to an article published by American Pharmaceutical Review in April 2023, single-use systems enhanced speed and efficiency, allowing for rapid bioprocessing setup and progressive manufacturing of multiple products at various scales within the same facility. In addition, the flexibility of SUS enabled more adaptability, allowing for seamless transitions from R&D to full-scale production or the manufacturing of different products. Thus, such benefits offered by single-use systems showed improvement throughput and scalability, thus enabling developers and manufacturers to bring products to market more quickly.
Moreover, the rising new product launches by key players further fuel the availability of single-use bioprocessing products in the market, which is expected to propel market growth. For instance, in April 2023, Merck launched the Ultimus Single-Use Process Container Film, which is designed with a proprietary woven nylon structure that provides extreme durability and leak resistance for single-use assemblies used for bioprocessing liquid applications. Such developments are anticipated to increase their adoption across the biopharmaceutical industry over the coming years, thereby contributing to market growth.
Therefore, owing to the factors above, such as the high demand for biopharmaceutical products, several advantages offered by single-use systems, and the increasing number of new product launches, the market studied is anticipated to grow over the forecast period. However, the issues related to leachable and extractable are likely to restrain the growth of the single-use bioprocessing market over the forecast period.
Single-use Bioprocessing Market Trends
Biopharmaceutical Manufacturer Segment is Expected to Witness Significant Growth Over the Forecast Period
The biopharmaceutical manufacturer segment is expected to grow significantly in the single-use bioprocessing market over the forecast period owing to factors such as the rising adoption of single-use technologies and systems, increasing demand for biologics, and growing company activities. In addition, some of the advantages offered by single-use technologies and products, such as reduced initial investment and research and development costs, low labor and material costs, and easy disposal over conventional bioprocessing methods, are also increasing their adoption across the biopharmaceutical industry. Additionally, these single-use bioprocessing plants produce a 35% more favorable carbon dioxide (CO2) balance than stainless steel reactors used in conventional bioprocessing and are highly adopted by the manufacturer.
The growing investment in research, development, and production of biopharmaceuticals by these companies is expected to be the key driving factor for biopharmaceutical manufacturers' high demand for single-use bio processors during the forecast period.
For instance, in April 2023, the Engineering and Physical Sciences Research Council (EPSRC), a part of the UK Research and Innovation (UKRI), granted a fund of GBP 12 million (~USD 15 million) to fund the Future Vaccines Manufacturing Hub for the next seven years, up to 2030. Further, the hub wants to make the United Kingdom the global center for vaccine discovery, development, and manufacture. This is expected to increase investments in the region further and drive the demand for single-use bioprocessing products such as filtration assemblies, disposable/single-use bioreactors, and disposable mixers.
The rising number of biologics approvals is also contributing to the increased demand for single-use bioreactors and technologies. For instance, in February 2023, the US FDA approved Bioverativ Therapeutics's Altuviio, a first-in-class, high-sustained factor VIII replacement therapy. It is indicated for routine prophylaxis, on-demand treatment to control bleeding episodes, and perioperative management (surgery) for adults and children with hemophilia A. In January 2022, Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, received approval for the Biologics License Application for Spikevax (COVID-19 Vaccine, mRNA) from the FDA to prevent COVID-19 in individuals 18 years of age and older.
Moreover, the companies are opening up single-use bioprocessing plants to expand their protein, cell line, and process development services. For instance, in April 2022, Thermo Fisher Scientific opened a 55,000 sq. ft single-use technology (SUT) facility in Ogden to increase the production of single-use bioprocess containers for developing vaccines and therapies. The plant provides additional capacity to produce various techniques and materials needed to develop emerging vaccines and breakthrough therapies. The facility manufactures customizable bioprocess container (BPC) systems for the delivery, processing, separation, storage, and transportation of liquids.
Therefore, due to factors such as the high number of biologics, growing strategic activities, and facility-expanding activities by the key players, the segment is expected to grow significantly over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant market share over the forecast period owing to the increasing research and development spending, the presence of large manufacturing units, the growing popularity of disposables, increasing healthcare expenditure, the well-established biopharmaceutical sector, and widespread availability of various single-use assembly products for bioprocessing supplied by regional market leaders.
Furthermore, an increase in investment by the US government to support the bioprocessing industry, the presence of prominent players in the country, and the rising number of product developments by the major players are projected to drive market growth during the forecast period.
The government authorities in Canada are highly focused on the biomanufacturing and pharma sectors to meet the rising demand for medicines and biologics. For instance, data published by the government of Canada in June 2023 stated that it invested about USD 2.1 billion in 36 projects in the biomanufacturing, vaccine, and therapeutics ecosystem, strengthening domestic pandemic response capabilities and life science innovation. The investments were spread across British Columbia, Alberta, Saskatchewan, Quebec, Ontario, and Atlantic Canada. Thus, such investments in biomanufacturing are likely to create a high demand for single-use assemblies in the country, as the single-use technologies can lower turn-around costs by reducing or eliminating the need for expensive stainless-steel equipment and the associated expenses of installation and cleaning. This is expected to ultimately fuel market growth over the forecast period.
The government is investing enormously in developing biopharmaceutical products, which is expected to drive the market for single-use bioreactors, containers, media, filtration assemblies, and others, propelling market growth. For instance, as per the fact sheet released in September 2022 by the Department of Health and Human Services, the government planned to invest USD 40 million to expand the role of biomanufacturing for active pharmaceutical ingredients (APIs), antibiotics, and the critical starting materials needed to produce essential medications and respond to pandemics.
Additionally, the rising company activities in establishing single-use bioprocessing plants and launching new products such as bioreactors, filtration assemblies, and other consumables are also expected to contribute to market growth in the region. For instance, in March 2024, Single Use Support, one of the leading providers of fluid management and freeze-thaw logistic solutions for the biopharmaceutical industry, expanded its services and opened a new office in Lexington, Massachusetts, equipped with a product showroom. Single Use Support’s portfolio includes its patented RoSS Shell for single-use bags, which are designed to reduce the risk of product loss and increase process efficiency during cold chain handling.
Similarly, in November 2022, Cardinal Health expanded its single-use device reprocessing facility in Riverview, Florida, with a capacity of 100,000 sq. ft. Thus, owing to such strategic expansions by the key players, the demand for single-use assemblies is likely to rise, thereby fueling market growth over the forecast period.
Therefore, owing to factors such as government investment activities and new product launches by the key players, the market studied is expected to grow significantly in the region over the forecast period.
Single-use Bioprocessing Industry Overview
The single-use bioprocessing market is moderately competitive and consists of several major players. Some companies are focusing on adopting various business strategies such as collaborations and new product launches to expand their offerings using single-use bioprocessing technologies and retain their position in the single-use bioprocessing market. Some of the companies in the market are Sartorius AG, Thermo Fisher Scientific, Danaher Corporation (Cytiva), Eppendorf AG, Merck KGaA, Boehringer Ingelheim International GmbH, and PBS Biotech.
Single-use Bioprocessing Market Concentration
-
Sartorius AG
-
Thermo Fisher Scientific
-
Eppendorf AG
-
Merck KGaA
-
Danaher Corporation (Cytiva)
*Disclaimer: Major Players sorted in no particular order
Single-use Bioprocessing Market News
- April 2024: SaniSure launched Fill4Sure, a custom single-use filling assembly that is designed to expedite drugs to market and build security, efficiency, and repeatability in drug product filling. The newly launched assembly provides a solution to the critical challenges drug manufacturers experience throughout the fill-finish process, such as high costs and limited speed. Hence, the launch of new single-use assemblies related to the fill-finish process is expected to boost the availability and accessibility of such solutions, propelling the growth of the market.
- March 2024: Getinge launched the Single-Use Production Reactor (SUPR) system that helps operators bring life-saving medicines faster to market, aiming to improve people’s quality of life. With this launch, the company intends to expand its bioreactor offering globally.
Single-use Bioprocessing Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumption and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Faster Implementation and Lower Risk of Product Cross-contamination
4.2.2 Increasing Demand for Biopharmaceuticals
4.2.3 Lower Costs and Lesser Environmental Impact of Single-use Bioprocessing Technologies
4.3 Market Restraints
4.3.1 Issues Related to Leachables and Extractables
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD)
5.1 By Product
5.1.1 Filtration Assemblies
5.1.2 Media Bags and Containers
5.1.3 Disposable/Single-use Bioreactors
5.1.4 Disposable Mixers
5.1.5 Other Products
5.2 By Application
5.2.1 Filtration
5.2.2 Cell Culture
5.2.3 Purification
5.2.4 Other Applications
5.3 By End User
5.3.1 Biopharmaceutical Manufacturers
5.3.2 Academic and Clinical Research Institutes
5.3.3 Other End Users
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Sartorius AG
6.1.2 Thermo Fisher Scientific
6.1.3 Danaher Corporation (Cytiva)
6.1.4 Eppendorf AG
6.1.5 Merck KGaA
6.1.6 3M
6.1.7 CESCO Bioengineering Co. Ltd
6.1.8 PBS Biotech Inc.
6.1.9 ABEC Inc.
6.1.10 Celltainer Biotech BV
6.1.11 Distek, Inc.
6.1.12 OmniBRx Biotechnologies
6.1.13 Boehringer Ingelheim International GmbH
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Single-use Bioprocessing Industry Segmentation
As per the scope of the report, single-use bioprocessing is a fast-moving technology used to develop disposable bioprocessing equipment to manufacture biopharmaceutical products. The single-use bioprocessing market is segmented by product, application, end user, and geography. By product, the segment is bifurcated into filtration assemblies, media bags and containers, disposable/single-use bioreactors, disposable mixers, and other products. The application segment is divided into filtration, cell culture, purification, and other applications. The end-user segment is segmented into biopharmaceutical manufacturers, academic and clinical research institutes, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
The report offers the value (USD) for the above segments.
| By Product | |
| Filtration Assemblies | |
| Media Bags and Containers | |
| Disposable/Single-use Bioreactors | |
| Disposable Mixers | |
| Other Products |
| By Application | |
| Filtration | |
| Cell Culture | |
| Purification | |
| Other Applications |
| By End User | |
| Biopharmaceutical Manufacturers | |
| Academic and Clinical Research Institutes | |
| Other End Users |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Single-use Bioprocessing Market Research FAQs
How big is the Single-use Bioprocessing Market?
The Single-use Bioprocessing Market size is expected to reach USD 1.36 billion in 2024 and grow at a CAGR of 16.26% to reach USD 2.9 billion by 2029.
What is the current Single-use Bioprocessing Market size?
In 2024, the Single-use Bioprocessing Market size is expected to reach USD 1.36 billion.
Who are the key players in Single-use Bioprocessing Market?
Sartorius AG, Thermo Fisher Scientific, Eppendorf AG, Merck KGaA and Danaher Corporation (Cytiva) are the major companies operating in the Single-use Bioprocessing Market.
Which is the fastest growing region in Single-use Bioprocessing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Single-use Bioprocessing Market?
In 2024, the North America accounts for the largest market share in Single-use Bioprocessing Market.
What years does this Single-use Bioprocessing Market cover, and what was the market size in 2023?
In 2023, the Single-use Bioprocessing Market size was estimated at USD 1.14 billion. The report covers the Single-use Bioprocessing Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Single-use Bioprocessing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Single-Use Bioprocessing Industry Report
Statistics for the 2024 Single-Use Bioprocessing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Single-Use Bioprocessing analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
